～高精度で小型化、起動時間を短縮し、使いやすさの向上を目指したデバイス～ デクスコムジャパン合同会社（本社：東京都目黒区、日本法人社長 浅野 元）は本日、リアルタイムCGM「Dexcom G7 CGMシステム」を発売しました。本製品は2023年9月に製造販売承認 ...

プレスリリース発表元企業：DexCom, Inc. 世界でベストセラーとなっているこのリアルタイムCGM1は、小型の一体型ウエアラブルと完全に再設計したモバイルアプリにより、機能と使いやすさが向上 新しいシステムは、市場最速のセンサーウオームアップ*を実現。

Dexcom’s leadership said Thursday that the company has fixed problems with its flagship glucose monitor after reports of quality issues with its latest G7 sensor. The diabetes technology company has ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Dexcom, Inc. (NASDAQ: DXCM), a global ...

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to ...

DexCom , Inc. (NASDAQ:DXCM) released its second quarter 2025 earnings presentation on July 30, highlighting continued revenue growth and key product developments. The continuous glucose monitoring ...

Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...

DexCom’s strategic focus remains on product innovation and market expansion. The FDA clearance for the extended-wear G7 sensor represents a significant competitive advantage, allowing users to wear ...

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...